Given the expanding population of patients with hypertriglyceridemia and other risk factors, IPE will have an increasingly major impact on cardiovascular risk reduction. As compared to more expensive therapies such as the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab, and evolocumab, IPE will be very favorable in terms of cost-effectiveness in both primary and secondary prevention. The gene discussed is PCSK9; the disease is hypertriglyceridemia.